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Clinical outcome, viral response and safety profile of chloroquine 
in COVID-19 patients — initial experience
Abstract
Introduction: Chloroquine and its analogues are currently being investigated for the treatment and post exposure prophylaxis of 
COVID-19 due to its antiviral activity and immunomodulatory activity.
Material and methods: Confirmed symptomatic cases of COVID-19 were included in the study. Patients were supposed to re-
ceive chloroquine (CQ) 500 mg twice daily for 7 days. Due to a change in institutional protocol, initial patients received chloroquine 
and subsequent patients who did not receive chloroquine served as negative controls. Clinical effectiveness was determined in 
terms of timing of symptom resolution and conversion rate of reverse transcriptase polymerase chain reaction (RT-PCR) on day 
14 and day 15 of admission.
Results: Twelve COVID-19 patients formed the treatment arm and 17 patients were included in the control arm. The duration 
of symptoms among the CQ treated group (6.3 ± 2.7 days) was significantly (p-value = 0.009) lower than that of the control 
group (8.9 ± 2.2 days). There was no significant difference in the rate of RT-PCR negativity in both groups. 2 patients out of 
12 developed diarrhea in the CQ therapy arm.  
Conclusion: The duration of symptoms among the treated group (with chloroquine) was significantly lower than that of the control 
group. RT-PCR conversion was not significantly different between the 2 groups.
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Introduction
COVID-19 was first detected in the Wuhan 
province of China and it has since traversed all 
natural barriers and spread to all continents of the 
world. COVID-19 is caused by the SARS-CoV-2 vi-
rus belonging to the family of Corona viruses and 
was previously referred to as the 2019 n-CoV. 
Within the limits of our current understanding, 
person to person spread of COVID-19 occurs 
through droplets and fomites [1–3]. The incuba-
tion period is presumed to be 2 to 14 days. The 
spectrum of disease ranges from a mild self-lim-
iting upper respiratory infection to Multi-Organ 
Dysfunction Syndrome [3–5].
Chloroquine (CQ) and hydroxychloro-
quine have been used in the management of 
COVID-19 due to their theoretical antiviral ac-
tivity [6–9]. China’s National Health Commission 
had reported that CQ was associated with reduced 
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progression of the disease and a decreased dura-
tion of symptoms [10, 11].
In light of the above, we considered it neces-
sary to undertake a study to describe the clinical 
course and treatment outcomes in COVID-19 pa-
tients treated with CQ. This was especially nec-
essary in a malaria-endemic country like India 
where CQ is easily available and doctors have 
extensive experience using it.
Objectives
Our primary objective was to study the clini-
cal and viral effectiveness of CQ in COVID-19 pos-
itive patients. The secondary objective was to 
study its safety profile.
Material and methods
Study design 
This was an observational case-control study 
done at a COVID referral center in western India.
Methodology and participants
All COVID-19 positive patients were hospi-
talized as per protocol. Symptomatic hospitalized 
RT-PCR confirmed COVID-19 patients (> 18 years 
old) were included in the study after providing 
informed written consent. The study protocol was 
approved by the Institute Ethics Committee vide. 
AIIMS/IEC/2020-21/1035. Originally designed to 
be a descriptive observational study, we initially 
recruited patients who received CQ as per our 
protocol. Due to changes in institutional guide-
lines, more patients could not be recruited into 
the CQ arm. Hence, patients who did not receive 
CQ served as controls in this study. Patients were 
excluded if they had a known hypersensitivity to 
CQ, cardiac arrhythmias, history of retinopathy, 
glucose-6-phosphate dehydrogenase deficiency, 
a prolonged corrected QT interval more than 
450 milliseconds, and baseline aspartate trans-
aminase, alanine transaminase levels > 5 times 
the upper limit of normal in the blood.  Pregnant 
patients, lactating mothers, bone marrow trans-
plant recipients, patients with stage 4 chronic 
kidney disease, and patients on maintenance 
hemodialysis were also excluded from the study.
The demographic details, clinical find-
ings, and investigation results were recorded in 
a pre-designed proforma. A detailed history in-
cluding symptoms and their duration was record-
ed. Study participants in the CQ group received 
CQ 500 mg twice daily for 7 days.
Repeat RT-PCR was done on day 14 and 
15. Clinical outcomes included the number of 
days of symptoms, RT-PCR conversion, and dis-
ease-related complications. The safety profile of 
therapy was determined in terms of the incidence 
of therapy-related complications.
Statistical methods
Data was analyzed using Python 3.6. Quanti-
tative data were presented as means and standard 
deviations (SD). Qualitative data were present-
ed as percentages. The distribution of data on 
categorical variables like the patient’s clinical 
parameters was expressed as frequency and per-
centages. The student’s t-test was used to assess 
the difference in duration of symptoms. Fisher’s 
exact test was used to compare viral clearance 
between the treatment group and the control 
group. A two-tailed p-value of less than 0.05 was 
considered statistically significant. 
Results
We received 120 patients during the study 
period of which 62 had RT-PCR done on day 
14 and 15 following national guidelines. Amongst 
those 62 patients, 29 of them were symptomatic 
without any comorbidities and were enrolled in 
our study as per protocol. Due to the unpredict-
able efficacy of chloroquine in COVID-19, it was 
decided that chloroquine would only be adminis-
tered to patients without comorbidities. In accor-
dance with institutional guidelines, we treated 
12 of them with CQ in addition to standard care. 
In the other group (17 out of 29), patients were 
treated with standard care as treatment protocol 
changed (Figure 1). 
Baseline demographic data of both groups is 
presented in Table 1. There were 29 patients in the 
study population with a mean age of 45.54 years 
(SD 15.3 years). There was a predominance of 
males in the study population. 24.13% of the 
study participants were smokers. Major symp-
toms included cough (71.4%), fever (59.52%), 
headache (14.2%), and hemoptysis (9.5%). 
Among the disease-related complications, 
2 patients (6.8%) had developed hypoxemic re-
spiratory failure. No patient had developed adult 
respiratory distress syndrome, septic shock, renal 
failure, liver failure, or multi-organ dysfunction 
syndrome. 2 out of 12 (16.6%) patients in the 
CQ-treated group developed diarrhea.
The duration of symptoms among the 
CQ-treated group (6.3 ± 2.7 days) was signifi-
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cantly (p-value = 0.009) lower than that of the 
control group (8.9 ± 2.2 days) (Figure 2). 
In our study, RT-PCR conversion on day 
15 was similar in both groups (p-value > 0.05) 
with conversion seen in 10 out of 12 patients 
on CQ (83.3%) compared to 16 out of 17 in the 
control group (94.4%) (Figure 3).
Discussion
In the current pandemic situation, there is a rel-
ative scarcity of high-quality reliable data on what 
constitutes optimal patient care in COVID-19. Drug 
therapy in COVID-19 remains important as the 
global treatment recommendations were largely 
based on empiric evidence and unpowered stud-
ies. Specific therapies which are currently consid-
ered for treatment include remdesivir, favipiravir, 
CQ/hydroxychloroquine, interleukin-6 pathway 
inhibitors, convalescent plasma, favipravir, inter-
feron-beta etc. The United States Food and Drug 
Administration has authorized conditional use of 
remdesivir for hospitalized children and adults 
with severe COVID-19. However, its anti-viral effect 
has only been proven in vitro and its use is sup-
ported by only a few randomized clinical trials [12].
CQ and hydroxychloroquine are currently 
being considered for the treatment and post-ex-








Males 9 (75%) 14 (82.3%) 0.669
Females 3 (25%) 3 (17.7%) 0.669
Smokers 2 (16.7%) 5 (29.4%) 0.664
Mean age, years [SD] 41.25 (18.04) 47.64 (15.30) 0.6
Mean duration of symptoms in days [SD] 6.3 (2.7) 8.9 (2.2) 0.009
RT-PCR conversion rate on day 14 and 15 10 (83.3) 16 (94.4) 0.521
Figure 1. Allocation of participants in the study
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posure prophylaxis of COVID-19 due to its theo-
retical antiviral and immunomodulatory activity. 
CQ increases intracellular pH, reduces T cell 
activation, impedes the pro-inflammatory sig-
naling pathway, and attenuates the production of 
TNF-alpha and interleukin-1. CQ was also found 
to inhibit the key steps of coronavirus entry into 
cells via angiotensin-converting enzyme 2 (ACE) 
receptor binding and membrane fusion [13, 14]. 
CQ has been used extensively in malaria treat-
ment especially in a malaria-endemic country like 
India, and it has been proven to have an excellent 
safety profile. This study is the first reported ex-
perience of CQ use for COVID-19 in India.
In our study, RT-PCR conversion on day 
14 and 15 was similar in both groups (p-value 
> 0.05).  Although Guatret et al showed early 
viral conversion in their study involving the 
use of CQ/HCQ, our results differed from this 
as we could not do serial RT-PCR testing owing 
to resource limitation inherent to a developing 
country [14]. Our result is concordant with the 
findings of Tang et al. who assessed the efficacy 
and safety of HCQ in 150 Chinese patients where 
they found that the negative conversion of RT-PCR 
was similar for their standard care group as well 
as the hydroxychloroquine group [15].
The duration of symptoms among the treated 
group was significantly lower than that of the 
control group (p-value = 0.009). There were no 
known studies in the literature that had reported 
time-to-symptom resolution. Our results suggest 
that, although CQ is unable to cause an early 
negative PCR conversion in patients, it assists in 
early symptom relief.
In a study published by van den Broek et 
al regarding the safety profile and adverse re-
actions, QTc interval prolongation greater than 
500 milliseconds was seen in 22 of 95 patients 
(25%) [16]. In our study, the only adverse event 
related to drug therapy was diarrhea in 2 out of 
12 patients. Tang et al also reported that diar-
rhea was the most common adverse event noted 
[15]. Due to known drug interactions between 
hydroxychloroquine and azithromycin, digox-
in, and metoprolol, we did not assess for these 
confounding factors in our study which may be 
elicited in larger trials.
Our results from the use of CQ in COVID-19 sug-
gest a limited albeit safe role in early symptom 
resolution in COVID-19. A shortened duration of 
symptoms with CQ might decrease the infectivity 
of the disease as aerosols generated by coughing 
are an important source of spread in COVID-19.
Strengths and limitations
This study, being the first reported expe-
rience of the use of CQ in the management of 
COVID-19 in India, and being bound by institu-
tional protocol in COVID-19 management, could 
only recruit a limited number of patients. How-
ever, since we could not find any larger studies 
from India regarding the use of HCQ/CQ, we 
Figure 3. Bar plot showing RT-PCR conversion rate at the end of 
2 weeks of hospitalization
Figure 2. Box-plot showing the distribution of time-to-symptom reso-
lution between the CQ and control arms
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proceeded with reporting our limited experience 
with it. Other limitations included the fact that 
this was a single center design with limited long 
term follow up. A shortened duration of symp-
toms with CQ might decrease the infectivity of 
the disease as aerosols generated by coughing 
are an important source of spread in COVID-19.
Conclusion
The duration of symptoms among the treat-
ed group (with CQ) was significantly lower than 
that of the control group, though RT-PCR con-
version was not significantly different between 
the two. CQ was used without serious adverse 
events. Larger and multicenter trials are needed 
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